The role of anti-IgE therapies in the treatment of asthma.
The prevalence of asthma, a chronic inflammatory disease often linked to allergy, is on the increase. The introduction of a blocking anti-IgE monoclonal antibody (omalizumab) as a new therapy has not only confirmed the pathogenic role of IgE in asthma but has also provided a novel therapy for a chronic severe disease where there are limited therapeutic options.
Babu
K Suresh
KS
Department of Respiratory Cell and Molecular Biology, Southampton General Hospital, Southampton SO16 6YD.
Holgate
Stephen T
ST
D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000628:therapy*; D002986:Clinical Trials as Topic; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D000069444:Omalizumab
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C026408:anti-IgE antibodies; D000069444:Omalizumab